After a brief delay last month, another piece of the Trump administration’s healthcare policy is falling into place. | On ...

Merz Therapeutics has launched a punchy marketing campaign for Parkinson’s disease drug Inbrija, working Muhammad Ali quotes ...

Bristol Myers Squibb is leaning heavily on its key newer products, grouped into its growth portfolio category, to weather the ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

On the branded side of things, Sun’s skin cancer offerings include Odomzo for basal cell carcinoma and Unloxcyt, an ...

Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales. | Astellas surpassed ...

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has ...

Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...

Miels succeeded Emma Walmsley to become GSK’s new CEO at the beginning of 2026, inheriting the role as GSK posted what he ...

The latest OXB agreement will help advance the company’s CAR-T therapies and provide a “reliable, scalable manufacturing ...

Bristol Myers Squibb has signed Kasey Keller for a partnership around Breyanzi, giving the U.S. | Bristol Myers Squibb has ...